Barclays PLC I Teos Therapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 113,211 shares of ITOS stock, worth $821,911. This represents 0.0% of its overall portfolio holdings.

Number of Shares

113,211

Previous 113,211 -0.0%

Holding current value

$821,911

Previous $1.16 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	SELL	$10.09 - $17.97 $91,455 - $162,880	-9,064 Reduced 7.41%	113,211 $1.16 Million
Q2 2024 Aug 14, 2024	SELL	$10.33 - $18.09 $2.32 Million - $4.05 Million	-224,144 Reduced 64.7%	122,275 $1.81 Million
Q1 2024 May 15, 2024	BUY	$9.89 - $13.64 $334,667 - $461,563	33,839 Added 10.83%	346,419 $4.73 Million
Q4 2023 Feb 15, 2024	SELL	$8.57 - $11.06 $83,488 - $107,746	-9,742 Reduced 3.02%	312,580 $3.42 Million
Q3 2023 Nov 07, 2023	BUY	$10.95 - $14.6 $81,489 - $108,653	7,442 Added 2.36%	322,322 $3.53 Million
Q2 2023 Aug 03, 2023	BUY	$12.93 - $18.05 $748,957 - $1.05 Million	57,924 Added 22.54%	314,880 $4.17 Million
Q1 2023 May 04, 2023	BUY	$13.02 - $22.62 $25,974 - $45,126	1,995 Added 0.78%	256,956 $3.5 Million
Q4 2022 Feb 13, 2023	BUY	$17.77 - $21.6 $588,506 - $715,348	33,118 Added 14.93%	254,961 $4.98 Million
Q3 2022 Nov 03, 2022	BUY	$18.6 - $27.25 $3.58 Million - $5.24 Million	192,220 Added 648.89%	221,843 $4.23 Million
Q2 2022 Aug 12, 2022	SELL	$16.57 - $35.1 $901,010 - $1.91 Million	-54,376 Reduced 64.73%	29,623 $610,000
Q1 2022 May 16, 2022	BUY	$31.92 - $47.45 $2.68 Million - $3.99 Million	83,999 New	83,999 $2.7 Million

Others Institutions Holding ITOS

# of Institutions

166

Shares Held

36.6M

Call Options Held

1.95M

Put Options Held

374K

View Full List

About iTeos Therapeutics, Inc.

Ticker ITOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,575,300
Market Cap $258M
Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...

More about ITOS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account